CN108728444A - 免疫调节性多核苷酸及其应用 - Google Patents

免疫调节性多核苷酸及其应用 Download PDF

Info

Publication number
CN108728444A
CN108728444A CN201710251198.4A CN201710251198A CN108728444A CN 108728444 A CN108728444 A CN 108728444A CN 201710251198 A CN201710251198 A CN 201710251198A CN 108728444 A CN108728444 A CN 108728444A
Authority
CN
China
Prior art keywords
cell
antibody
cancer
tumour
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201710251198.4A
Other languages
English (en)
Chinese (zh)
Inventor
黄涛
邵彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Huapu Biotechnology Co Ltd
Original Assignee
Changchun Huapu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Huapu Biotechnology Co Ltd filed Critical Changchun Huapu Biotechnology Co Ltd
Priority to CN201710251198.4A priority Critical patent/CN108728444A/zh
Priority to US16/484,090 priority patent/US11326170B2/en
Priority to EP18787826.9A priority patent/EP3612633A4/en
Priority to CN201880025806.2A priority patent/CN110753756B/zh
Priority to JP2019556339A priority patent/JP7251017B2/ja
Priority to PCT/CN2018/083435 priority patent/WO2018192505A1/en
Publication of CN108728444A publication Critical patent/CN108728444A/zh
Priority to US17/662,392 priority patent/US12460208B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201710251198.4A 2017-04-18 2017-04-18 免疫调节性多核苷酸及其应用 Withdrawn CN108728444A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201710251198.4A CN108728444A (zh) 2017-04-18 2017-04-18 免疫调节性多核苷酸及其应用
US16/484,090 US11326170B2 (en) 2017-04-18 2018-04-17 Immunomodulatory polynucleotides and uses thereof
EP18787826.9A EP3612633A4 (en) 2017-04-18 2018-04-17 IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF
CN201880025806.2A CN110753756B (zh) 2017-04-18 2018-04-17 免疫调节性多核苷酸及其应用
JP2019556339A JP7251017B2 (ja) 2017-04-18 2018-04-17 免疫調節ポリヌクレオチド及びその使用
PCT/CN2018/083435 WO2018192505A1 (en) 2017-04-18 2018-04-17 Immunomodulatory polynucleotides and uses thereof
US17/662,392 US12460208B2 (en) 2017-04-18 2022-05-06 Immunomodulatory polynucleotides and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710251198.4A CN108728444A (zh) 2017-04-18 2017-04-18 免疫调节性多核苷酸及其应用

Publications (1)

Publication Number Publication Date
CN108728444A true CN108728444A (zh) 2018-11-02

Family

ID=63855596

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710251198.4A Withdrawn CN108728444A (zh) 2017-04-18 2017-04-18 免疫调节性多核苷酸及其应用
CN201880025806.2A Active CN110753756B (zh) 2017-04-18 2018-04-17 免疫调节性多核苷酸及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880025806.2A Active CN110753756B (zh) 2017-04-18 2018-04-17 免疫调节性多核苷酸及其应用

Country Status (5)

Country Link
US (1) US11326170B2 (https=)
EP (1) EP3612633A4 (https=)
JP (1) JP7251017B2 (https=)
CN (2) CN108728444A (https=)
WO (1) WO2018192505A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113058033A (zh) * 2019-12-16 2021-07-02 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CN113521267A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种covid-19重组蛋白疫苗组合物及应用
CN113521274A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种covid-19灭活疫苗组合物及应用
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN115368463A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024152998A1 (zh) * 2023-01-19 2024-07-25 华普生物技术(河北)股份有限公司 CpG佐剂在制备新型冠状病毒疫苗中的应用
WO2025113554A1 (zh) * 2023-11-30 2025-06-05 华普石家庄医药有限公司 一种水痘带状疱疹疫苗组合物及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210122778A1 (en) * 2019-10-21 2021-04-29 Northwestern University Spherical nucleic acids with dendritic ligands
CN113521275B (zh) * 2020-04-17 2024-06-25 北京科兴中维生物技术有限公司 一种复合佐剂及使用该复合佐剂的新冠covid-19重组蛋白疫苗
CN113521273B (zh) * 2020-04-17 2026-04-10 北京科兴中维生物技术有限公司 一种使用含有CpG寡聚脱氧核苷酸的复合佐剂的新冠COVID-19灭活疫苗
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN114807153A (zh) * 2022-05-13 2022-07-29 南京吉盛澳玛生物医药有限公司 多种具有免疫刺激活性的CpG寡聚脱氧核苷酸及其应用
US20230404642A1 (en) * 2022-06-01 2023-12-21 Syncromune, Inc. Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用
AU2024287014A1 (en) 2023-06-07 2026-01-22 Sichuan Clover Biopharmaceuticals, Inc. Rsv vaccine composition, method and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084310A (zh) * 2004-10-20 2007-12-05 科勒制药集团公司 半软c类免疫刺激性寡核苷酸
CN101610671A (zh) * 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007119815A1 (ja) 2006-04-14 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Ｔｏｌｌ様受容体９作動薬
EP2170353B1 (en) * 2007-05-18 2015-06-03 AdiuTide Pharmaceuticals GmbH Phosphate-modified oligonucleotide analogs with immunostimulatory activity
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN102719436A (zh) * 2012-06-27 2012-10-10 南开大学 一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
ES2699410T3 (es) * 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR
KR102230325B1 (ko) * 2015-09-30 2021-03-19 시오노기 앤드 컴파니, 리미티드 면역 부활 활성을 갖는 핵산 유도체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084310A (zh) * 2004-10-20 2007-12-05 科勒制药集团公司 半软c类免疫刺激性寡核苷酸
CN101610671A (zh) * 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANGYANG等: "《CpG oligodeoxynucleotides with double stem-loops show strong immunostimulatory activity》", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113058033A (zh) * 2019-12-16 2021-07-02 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CN113521267A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种covid-19重组蛋白疫苗组合物及应用
CN113521274A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种covid-19灭活疫苗组合物及应用
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
WO2022228560A1 (zh) * 2021-04-30 2022-11-03 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN115368463A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024152998A1 (zh) * 2023-01-19 2024-07-25 华普生物技术(河北)股份有限公司 CpG佐剂在制备新型冠状病毒疫苗中的应用
WO2025113554A1 (zh) * 2023-11-30 2025-06-05 华普石家庄医药有限公司 一种水痘带状疱疹疫苗组合物及其用途

Also Published As

Publication number Publication date
EP3612633A1 (en) 2020-02-26
JP7251017B2 (ja) 2023-04-04
JP2020516305A (ja) 2020-06-11
US11326170B2 (en) 2022-05-10
CN110753756B (zh) 2023-09-01
WO2018192505A1 (en) 2018-10-25
US20200002704A1 (en) 2020-01-02
EP3612633A4 (en) 2021-04-28
CN110753756A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
CN108728444A (zh) 免疫调节性多核苷酸及其应用
JP6991857B2 (ja) Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
KR102710962B1 (ko) 절단성 링커를 포함하는 화합물 및 이들의 용도
TWI674904B (zh) 用於免疫療法的化合物及組合物
EP3763742B1 (en) Anti-pd-l1 conjugates for treating tumors
US11220552B2 (en) Anti-CD20 combinations for treating tumors
JP2017521421A (ja) 癌を治療するための併用療法組成物及び方法
JP2003535907A (ja) 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
JP2017521420A (ja) 腫瘍を治療するための抗ｐｄ−ｌ１組み合わせ
TW201408323A (zh) 用於靶向免疫療法的化合物
Kurokawa et al. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy
CN104861063A (zh) 靶向her2阳性肿瘤的化合物和组合物
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
US12460208B2 (en) Immunomodulatory polynucleotides and uses thereof
CN104861064A (zh) 靶向表达egfr的肿瘤的化合物和组合物
HK1242199B (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing City, Jiangsu Province, 210031

Applicant after: Nanjing Huapu Biotechnology Co.,Ltd.

Address before: Room 306, block a, incubation building, 191 Chaoqun street, Changchun City, Jilin Province

Applicant before: CHANGCHUN HUAPU BIOTECHNOLOGY Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province

Applicant after: Huapu Biotechnology (Jiangsu) Co.,Ltd.

Address before: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing City, Jiangsu Province, 210031

Applicant before: Nanjing Huapu Biotechnology Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 051430 7-9/F, Building A2, No. 769, Taihang South Street, Shijiazhuang Hi tech Industrial Development Zone, Hebei Province

Applicant after: Huapu Biotechnology (Hebei) Co.,Ltd.

Address before: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province

Applicant before: Huapu Biotechnology (Jiangsu) Co.,Ltd.

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20181102